HPLC-MS/MS法测定人体血浆中扎托布洛芬的浓度

目的: 建立灵敏、快速和选择性高的高效液相色谱串联质谱法(HPLC-MS/MS)测定人血浆中扎托布洛芬浓度。 方法: 采用Agilent ZORBAX Eclipse Plus-C₁₈(150 mm×4.6 mm,5 μm)色谱柱,流动相为甲醇-0.1%甲酸水溶液(90∶10,v/v),地西泮为内标,以多反应监测(MRM)扫描方式进行监测,监测离子质荷比:扎托布洛芬m/z 299.2→m/z 225.2,地西泮m/z 285.1→m/z 193.1,血浆样品经乙腈沉淀蛋白后取上清液进样。 结果: 血浆中扎托布洛芬线性范围为0.02~20.0 μg·mL^-1,低、中、高3个浓度日内、日间精密度均小于10%。 结论: 本方法灵敏度高,选择性强,分析时间短,适用于人血浆中扎托布洛芬的浓度测定。

Objective: To develop and validate a method for the determination of zaltoprofen in human plasma by HPLC-MS/MS. Methods: An Agilent ZORBAX Eclipse Plus-C₁₈(150 mm×4.6 mm,5 μm) was adopted with the mobile phase of methanol and 0.1% formic acid(90∶10,v:v).Diazepam was used as internal standard.Multiple reaction monitoring(MRM) mode was employed,and the transition of m/z was m/z 299.2→m/z 225.2 for zaltoprofen,m/z 285.1→m/z193.1 for diazapan.The plasma samples were simply pretreated by protein precipitation. Results: The calibration curves of zaltoprofen was linear in the range of 0.02-20.0 μg·mL^-1.RSDs of the inter-day and intra-day precisions of low,medium and high concentrations were all less than 10%. Conclusion: The method is sensitive,specific,rapid and suitable for the determination of zaltoprofen in human plasma.

1 Hatori M,Kokubun S.The long-term efficacy and tolerability of the new anti-inflammatory agent zaltoprofen in rheumatoid arthritis.Curr Med Res Opin,1998,14(2):79
2 Tsurumi K,Kyuki K,Niwa M,et al.Pharmacological investigations of the new antiinflammatory agent 2- propionic acid.Arzneimittelforschung,1986,36(12):1796
3 Pareek A,Gupta AK,Chandurkar NB,et al.Zaltoprofen,a noninferior alternative to diclofenac for the treatment of primary knee osteoarthritis-a comparative evaluation of efficacy and safety in a 4-week,multicentric,randomized,double-blind,double-dummy trial.Exp Opin Pharmacother,2011,12(7):1007
4 Kawai S,Nishida S,Kato M,et al.Comparison of cyclooxygenase-1 and-2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells.Eur J Pharmacol,1998,347(1):87
5 Kawai S.Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs:a clinical consideration.Inflamm Res,1998,47 Suppl 2:S102
6 Hirate K,Uchida A,Ogawa Y,et al.Zaltoprofen,a non-steroidal anti-inflammatory drug,inhibits bradykinin-induced pain responses without blocking bradykinin receptors.Neurosci Res,2006,54(4):288
7 Tang H,Inoue A,Oshita K,et al.Zaltoprofen inhibits bradykinin-induced responses by blocking the activation of second messenger signaling cascades in rat dorsal root ganglion cells.Neuropharmacology,2005,48(7):1035
8 Miskai M,Makoto I,Hiroshi U.NSAID zaltoprofen possesses novel anti-nociceptive mechanism through blockage of B2-type bradykinin receptor in nerve endings.Neurosci Lett,2006,397(3):249
9 Kohno T.Zaltoprofen inhibits bradykinin-mediated enhancement of glutamate receptor activity in substantia gelatinosa neurons.Anesth Anal,2011,113(2):412
10 Azuma A,Kudoh S,Nakashima M,et al.A double-blind study of zaltoprofen for the treatment of upper respiratory tract infection.Pharmacology,2010,85(1):41
11 Choi SO,Um SY,Jung SH,et al.Column-switching high-performance liquid chromatographic method for the determination of zaltoprofen in rat plasma.J Chromatogr B,2006,830(2):301
12 Yang HK,Kim SY,Kim JS,et al.Application of column-switching HPLC method in evaluating pharmacokinetic parameters of zaltoprofen and its salt.Biomed Chromatogr,2009,23(5):537
13 Lee HW,Seo JH,Kim YW,et al.Determination of zaltoprofen in human plasma by liquid chromatography with electrospray tandem mass spectrometry:Application to a pharmacokinetic study.Rapid Commun Mass Spectrom,2006,20(18):2675